Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

ConditionSquamous Cell Cancer of Head and Neck (SCCHN)

Trial statusRecruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age18-70

SponsorSun Yat-sen University

About this trial

The main objective of this trial was to determine the value of concurrent chemoradiotherapy for Intermediate-risk head and neck squamous cell carcinoma

Eligibility criteria

Qualifiers

Stages

white blood cell count > 4×109/L

hemoglobin > 120g/L in males, 110g/L in females

platelet count > 100×109/L

Disqualifiers

unstable heart disease that requires treatment

kidney disease

chronic hepatitis

poorly controlled diabetes (fasting blood glucose > 1.5×ULN)

Trial design

Treatments tested in this trial

Cisplatin

Treatment groups

386 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Sun Yat-sen University

Lead sponsor

Source ClinicalTrials.gov